News & Announcements

AMP RA Lupus Year 6

The Accelerating Medicines Partnership (AMP) is extending the Rhemautoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) & Related Autoimmune Disorders program to a sixth year to further analyze the existing dataset.

Kidney injury detection

FNIH Biomarkers Consortium and Critical Path Institute achieve the first ever qualification of a clinical safety biomarker by the U.S. Food and Drug Administration.

Dr. Elias Zerhouni

The FNIH Board of Directors elected distinguished scientific leader, Dr. Zerhouni, as its newest member. His appointment took effect on January 1, 2019.

Spotlight

Stevie Award

Learn how the AMP RA/Lupus project is helping patients with rheumatoid arthritis and lupus.

 FNIH Rated #1 Charity

The FNIH is delighted to once again earn the highest, 4-star rating from Charity Navigator.

 

Front Page: